Actively Recruiting
Study of NNC0487-0111 Weekly Injection for Weight Loss in Japanese Adults With Overweight or Obesity
Led by Novo Nordisk A/S · Updated on 2026-09-16
400
Participants Needed
26
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new medicine called NNC0487-0111 to see if it is safe and effective for helping adults in Japan with excess body weight, including those with overweight or obesity. This Phase 3 clinical study compares NNC0487-0111 with a placebo, a treatment that does not contain active medicine, to understand its effects. The study includes participants with and without type 2 diabetes or knee osteoarthritis, following specific criteria for these groups. Participants receive either NNC0487-0111 or a placebo, both given as weekly injections under the skin using pre-filled pen injectors on the thigh, abdomen, or upper arm. The treatment is combined with a reduced-calorie diet and increased physical activity. Participants receive one of four dose levels of NNC0487-0111 or a matching placebo. The study treatment continues once weekly for up to 84 weeks. During the study, participants are regularly monitored through visits where body weight and waist circumference are measured. The main outcome is the relative change in body weight from the start of the study to week 84. Secondary outcomes include changes in waist size. Safety and adherence are also monitored throughout the study period, which lasts approximately 84 weeks from baseline to the final assessment.
CONDITIONS
Brief Title
AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here